Related Experiment Video
Updated: Feb 24, 2026

Isolation, Transfection, and Culture of Primary Human Monocytes
Published on: December 16, 2019
[Pathogenic mechanisms for fat redistribution in patients with HIV disease]
Daniela Adriana Ion1, Laura Ioana Chivu, R D Chivu
1Universitatea de Medicing si Farmacie Carol Davila Bucureşti, Facultatea de Medicină, Disciplina de Fiziopatologie.
Insights
Lipodystrophy syndrome, encompassing morphological and metabolic issues in HIV patients, involves distinct pathways. Key factors include adipocyte differentiation impairment, cytokine dysregulation, and mitochondrial toxicity.
Area of Science:
- Endocrinology
- Virology
- Metabolic Disorders
Context:
- Lipodystrophy syndrome is traditionally associated with HIV disease and highly active antiretroviral therapy (HAART).
- It encompasses both morphological (lipoatrophy, lipohypertrophy) and metabolic (dyslipidemia, insulin resistance) disturbances.
- Emerging evidence indicates these components may have distinct pathological pathways.
Purpose:
- To explore the complex pathogenesis of lipodystrophy syndrome in HIV patients.
- To highlight distinct pathological pathways underlying morphological and metabolic disturbances.
- To identify key molecular and cellular mechanisms involved in lipodystrophy.
Summary:
- Lipodystrophy syndrome, affecting HIV patients, presents with varied morphologic and metabolic issues.
- Pathogenesis involves impaired adipocyte differentiation (e.g., altered SREBP1c expression), dysregulated adipokines, and inflammation.
- Mechanisms include proinflammatory cytokine-mediated adipocyte apoptosis (TNF-alpha, IL-6) and mitochondrial toxicity.
Impact:
- Clarifies the distinct pathophysiological mechanisms of lipodystrophy components.
- Provides insights into potential therapeutic targets for managing HIV-associated lipodystrophy.
- Advances understanding of metabolic and endocrine complications in chronic viral infections.
Abstract:
Lipodystrophy syndrome is a common term in the literature traditionally used to describe several morphologic (lipoatrophy; lipohypertrophy; mixed syndrome) and metabolic (dyslipidemia, insulin resistance) disturbances found in patients with HIV disease, with or without treatment with highly active antiretroviral therapy (HAART). Increasing evidence suggests these disorders, though commonly clustering in a syndrome pattern, have distinct pathologic pathways and can occur independently of each other. The pathogenesis of these disorders is complex, but recent hypotheses and evidence suggest that impairment to adipocyte differentiation, in particular through alterations in the expression of the transcription factor sterol responsive element binding protein-lc (SREBP1c), impairment of adipokine regulation, unopposed production of proinflammatory cytokines, adipocyte apoptosis mediated by proinflammatory cytokines such as tumor necrosis factor (TNF-alpha) and IL-6, dysregulation of 1l-beta-hydroxysteroid dehydrogenase, and mitochondrial toxicity may play a role.
Related Concept Videos
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Sexually Transmitted Infections
Cholesterol: Significance and Regulation
Considering cholesterol and...

